Introduction of new lipid lowering drugs, such as PCSK9 inhibitors, bempedoic acid and incliserin, will lead to better treatment and outcomes in patients affected by advanced atherosclerosis; however, the literature underlines the strict relationship between PCSK9 and APOE in both lipid profile and vascular disease [43,44]. This evidence concerns the gene PCSK9 and atherosclerosis.